Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 1,387 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 1,387 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $12.04, for a total value of $16,699.48. Following the completion of the sale, the chief financial officer now directly owns 71,832 shares of the company’s stock, valued at $864,857.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $68,256.24.

Nurix Therapeutics Stock Down 3.6 %

NRIX traded down $0.45 during trading on Tuesday, reaching $12.02. The stock had a trading volume of 1,505,032 shares, compared to its average volume of 943,265. The firm has a market capitalization of $590.80 million, a price-to-earnings ratio of -4.61 and a beta of 2.06. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $18.12. The stock has a 50 day moving average of $13.66 and a two-hundred day moving average of $9.79.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The firm had revenue of $15.16 million during the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Wells Fargo & Company decreased their target price on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, February 16th. Morgan Stanley lifted their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. HC Wainwright decreased their target price on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Robert W. Baird lifted their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.33.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC lifted its holdings in shares of Nurix Therapeutics by 23.2% in the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after purchasing an additional 601,952 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Nurix Therapeutics by 176.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after purchasing an additional 440,112 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Nurix Therapeutics by 48.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after purchasing an additional 184,617 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Nurix Therapeutics by 1,012.4% in the third quarter. GSA Capital Partners LLP now owns 195,420 shares of the company’s stock valued at $1,536,000 after purchasing an additional 177,852 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 192.7% in the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after purchasing an additional 107,719 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.